| Maintenance therapy in AML: the past, the present and the future M Molica, M Breccia, R Foa, E Jabbour, TM Kadia American journal of hematology 94 (11), 1254-1265, 2019 | 84 | 2019 |
| Ponatinib: a review of efficacy and safety F Massaro, M Molica, M Breccia Current cancer drug targets 18 (9), 847-856, 2018 | 75 | 2018 |
| Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment M Breccia, M Molica, I Zacheo, A Serrao, G Alimena Annals of hematology 94, 393-397, 2015 | 70 | 2015 |
| Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC) SG Morano, R Latagliata, C Girmenia, F Massaro, P Berneschi, ... Supportive Care in Cancer 23, 3289-3295, 2015 | 63 | 2015 |
| TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge? M Molica, C Mazzone, P Niscola, P De Fabritiis Frontiers in oncology 10, 610820, 2021 | 52 | 2021 |
| How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review M Breccia, M Molica, G Alimena Leukemia research 38 (12), 1392-1398, 2014 | 47 | 2014 |
| Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free … M Breccia, L Luciano, R Latagliata, F Castagnetti, D Ferrero, F Cavazzini, ... Leukemia Research 38 (10), 1173-1176, 2014 | 43 | 2014 |
| Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia M Molica, E Scalzulli, G Colafigli, R Foà, M Breccia Therapeutic advances in hematology 10, 2040620719826444, 2019 | 42 | 2019 |
| Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia S Molica, G Cutrona, G Vitelli, R Mirabelli, M Molica, G Digiesi, D Ribatti, ... Leukemia research 31 (11), 1575-1578, 2007 | 41 | 2007 |
| SARS‐CoV‐2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies M Molica, C Mazzone, I Cordone, A Pasquale, P Niscola, P de Fabritiis British Journal of Haematology 190 (1), e5, 2020 | 35 | 2020 |
| Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL) S Molica, G Digiesi, A Antenucci, L Levato, R Mirabelli, M Molica, ... Leukemia research 36 (4), 443-447, 2012 | 35 | 2012 |
| How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes F Massaro, M Molica, M Breccia Expert Review of Hematology 10 (2), 155-159, 2017 | 34 | 2017 |
| Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia S Molica, G Digiesi, C Battaglia, G Cutrona, A Antenucci, M Molica, ... European Journal of Haematology 85 (4), 314-320, 2010 | 32 | 2010 |
| CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin M Molica, S Perrone, C Mazzone, P Niscola, L Cesini, E Abruzzese, ... Cancers 13 (13), 3214, 2021 | 31 | 2021 |
| Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: identification of risk … G Caocci, O Mulas, M Annunziata, L Luciano, M Bonifacio, EM Orlandi, ... American journal of hematology 93 (7), E159-E161, 2018 | 29 | 2018 |
| Systematic review of dasatinib in chronic myeloid leukemia M Breccia, A Salaroli, M Molica, G Alimena OncoTargets and therapy, 257-265, 2013 | 28 | 2013 |
| Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy L Cicconi, M Breccia, L Franceschini, R Latagliata, M Molica, M Divona, ... Annals of hematology 97, 1797-1802, 2018 | 27 | 2018 |
| Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells M Breccia, MS De Propris, C Stefanizzi, S Raponi, M Molica, G Colafigli, ... Annals of hematology 93, 1819-1823, 2014 | 27 | 2014 |
| Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? M Molica, A Serrao, R Saracino, I Zacheo, C Stingone, G Alimena, ... Annals of hematology 93, 1951-1952, 2014 | 25 | 2014 |
| Prognostic factors associated with a stable MR4. 5 achievement in chronic myeloid leukemia patients treated with imatinib M Breccia, M Molica, G Colafigli, F Massaro, L Quattrocchi, R Latagliata, ... Oncotarget 9 (7), 7534, 2018 | 23 | 2018 |
